52.46
-0.05 (-0.10%)
| Previous Close | 52.51 |
| Open | 52.35 |
| Volume | 1,256,859 |
| Avg. Volume (3M) | 1,892,000 |
| Market Cap | 5,522,916,352 |
| Price / Book | 12.30 |
| 52 Weeks Range | |
| Earnings Date | 27 Oct 2025 |
| Diluted EPS (TTM) | -2.54 |
| Total Debt/Equity (MRQ) | 1.92% |
| Current Ratio (MRQ) | 6.55 |
| Operating Cash Flow (TTM) | -138.61 M |
| Levered Free Cash Flow (TTM) | -48.76 M |
| Return on Assets (TTM) | -27.09% |
| Return on Equity (TTM) | -108.40% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Metsera, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.00 |
|
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 13.06% |
| % Held by Institutions | 77.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mic Capital Management Uk Llp | 30 Jun 2025 | 4,539,540 |
| Alpha Wave Global, Lp | 30 Jun 2025 | 2,384,050 |
| Viking Global Investors Lp | 30 Jun 2025 | 1,616,612 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 57.00 (Leerink Partners, 8.65%) | Hold |
| Median | 53.50 (1.98%) | |
| Low | 50.00 (B of A Securities, -4.69%) | Buy |
| Average | 53.50 (1.98%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 43.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 24 Sep 2025 | 57.00 (8.65%) | Hold | 52.50 |
| 09 Sep 2025 | 77.00 (46.78%) | Buy | 36.72 | |
| B of A Securities | 28 Aug 2025 | 50.00 (-4.69%) | Buy | 35.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Sep 2025 | Announcement | Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 |
| 22 Sep 2025 | Announcement | Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio |
| 22 Sep 2025 | CNBC | Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera |
| 11 Sep 2025 | Announcement | Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting |
| 27 Aug 2025 | Announcement | Metsera to Present at Upcoming September Investor Conferences |
| 28 Jul 2025 | Announcement | Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |